Many people on these weight-loss drugs - which include Ozempic, Wegovy, Zepbound and Mounjaro ... even though some have faced declines in their stock prices at times attributable to such concerns.

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Novo Nordisk (NVO) stock slipped after ate-stage trial data for a higher-dose version of its popular obesity therapy, ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Novo Nordisk's STEP UP trial shows semaglutide 7.2 mg delivers superior weight loss and safety compared to lower doses and ...

Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...

Novo Nordisk said that patients taking a higher dose of its blockbuster obesity drug Wegovy lost more weight than those on ... s top international stock and ETF picks today. We sell different ...

In this photo illustration, the injectable weight-loss medication Wegovy is available at New City Halstead Pharmacy on April 24, 2024 in Chicago. Scott Olson/Getty Images, FILE Officials were ...

Both Wegovy ... Novo’s stock fell slightly in early December after a trial sponsored by Lilly found that patients who took Zepbound lost 20.2% of their body weight, on average, compared with ...